Ramucirumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | VEGFR2 (KDR) |
| Clinical data | |
| Trade names | Cyramza |
| Other names | LY3009806, IMC-1121B |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614026 |
| License data |
|
| Routes of administration | Intravenous infusion |
| Drug class | Antineoplastic agents |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6374H9864N1692O1996S46 |
| Molar mass | 143609.63 g·mol−1 |
| (what is this?) (verify) | |
Ramucirumab(), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. Ramucirumab was developed by ImClone Systems.